This clinical trial is focused on studying certain types of blood cancer known as Philadelphia-negative chronic myeloproliferative neoplasms. These include essential thrombocythemia, polycythemia vera, and prefibrotic myelofibrosis. The treatment being tested in this study is a medication called atorvastatin, which is commonly used to lower cholesterol levels. In this trial, atorvastatin is being used to see if it can help reduce inflammation and improve blood cell counts in patients who are already receiving the best available therapy for their condition.

The purpose of the study is to investigate the effects of adding atorvastatin to the current treatment regimen for these blood cancers. Participants in the study will take atorvastatin in the form of film-coated tablets, which are taken orally. The study will compare the results of those taking atorvastatin with those who are not, to see if there are any differences in inflammation markers and blood cell counts. The study will last for a period of up to 24 months, during which time participants will be monitored regularly.

Throughout the study, researchers will focus on measuring certain indicators of inflammation, such as hs-CRP and inflammatory cytokines, as well as blood cell counts, including leukocyte and platelet counts. The study aims to provide more information on whether atorvastatin can be a beneficial addition to the treatment of these specific types of blood cancer. Participants will be closely monitored to ensure their safety and to gather data on the effectiveness of the treatment.